Jubilant's Radiopharma business receives NDA approval for Technetium Mertiatide Injection

Jubilant Pharmova Limited's wholly owned subsidiary Jubilant Draximage Inc ('Company') has received approval from the US FDA with regards to the Company's new drug application (NDA) submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Kit for the Preparation of Technetium (Tc 99m) Mertiatide Injection.

The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities, renal failure, urinary tract obstruction, and calculi in adults and pediatric patients aged 30 days and older. The product enables providing renal function, split function, renal angiograms, and renogram curves for whole kidney and renal cortex.

This approval is effective from Jan 30, 2023.

Shares of Jubilant Pharmova Limited was last trading in BSE at Rs. 351.95 as compared to the previous close of Rs. 336.80. The total number of shares traded during the day was 3637 in over 462 trades.

The stock hit an intraday high of Rs. 358.55 and intraday low of 333.90. The net turnover during the day was Rs. 1254203.00.

Source : Equity Bulls

Keywords

JubilantPharmova INE700A01033 USFDA ANDAApproval JubilantDraximageInc FDCA TechnetiumMertiatideInjection